A phase I clinical trial (NCT01935843) demonstrated the safety and feasibility of HER2 CAR T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers [36]. This evidence concerns the gene ERBB2 and familial pancreatic carcinoma.